SEARCH

SEARCH BY CITATION

References

  • Acharya JN, Satishchandra P, Shankar SK. (1995) Familial progressive myoclonus epilepsy: clinical and electrophysiologic observations. Epilepsia 36:429434.
  • Aykutlu E, Baykan B, Gürses C, Bebek N, Büyükbabani N, Gökyigit A. (2005) Add-on therapy with topiramate in progressive myoclonic epilepsy. Epilepsy Behav 6:260263.
  • Berkovic SF, Andermann F, Carpenter S, Wolfe LS. (1986) Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med 315:296305.
  • Berkovic SF, Mazarib A, Walid S, Neufeld MY, Manelis J, Nevo Y, Korczyn AD, Yin J, Xiong L, Pandolfo M, Mulley JC, Wallace RH. (2005) A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. Brain 128:652658.
  • Bloch M, Hayden MR. (1990) Opinion: predictive testing for Huntington disease in childhood: challenges and implications. Am J Hum Genet 46:14.
  • Crest C, Dupont S, Leguern E, Adam C, Baulac M. (2004) Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 62:640643.
  • Cruz JA. (2000) Dietary habits and nutritional status in adolescents over Europe—Southern Europe. Eur J Clin Nutr 54(Suppl 1):S29S35.
  • De Haan GJ, Halley DJ, Doelman JC, Geesink HH, Augustijn PB, Jager-Jongkind AD, Majoie M, Bader AJ, Leliefeld-Ten Doeschate LA, Deelen WH, Bertram E, Lehesjoki AE, Lindhout D. (2004) Univerricht-Lundborg disease: underdiagnosed in the Netherlands. Epilepsia 45:10611063.
  • Edwards MJ, Hargreaves IP, Heales SJ, Jones SJ, Ramachandran V, Bhatia KP, Sisodiya S. (2002) N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects. Neurology 59:14471449.
  • Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. (1983) “Baltic” myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 2:838842.
  • Faught E. (2003) Clinical presentations and phenomenology of myoclonus. Epilepsia 44 (Suppl 11):712.
  • Ferlazzo E, Magaudda A, Striano P, Vi-Hong N, Serra S, Genton P. (2007) Long-term evolution of EEG in Unverricht-Lundborg disease. Epilepsy Res 73:219227.
  • Franceschetti S, Antozzi C, Binelli S, Carrara F, Nardocci N, Zeviani M, Avanzini G. (1993) Progressive myoclonus epilepsies: an electroclinical, biochemical, morphological and molecular genetic study of 17 cases. Acta Neurol Scand 87:219223.
  • Frucht SJ, Louis ED, Chuang C, Fahn S. (2001) A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 57:11121114.
  • Genton P, Michelucci R, Tassinari CA, Roger J. (1990) The Ramsay Hunt syndrome revisited: Mediterranean myoclonus versus mitochondrial encephalomyopathy with ragged-red fibers and Baltic myoclonus. Acta Neurol Scand 81:815.
  • Genton P, Gelisse P. (2000) Antimyoclonic effect of levetiracetam. Epileptic Disord 2:209212.
  • Gouider R, Ibrahim S, Fredj M, Gargouri A, Saidi H, Ouezzani R, Malafosse A, Yahiaoui M, Grid D, Mrabet A. (1998) [Unverricht-Lündborg disease: clinical and electrophysiologic study of 19 Maghreb families] Rev Neurol (Paris) 154:503507. (Article in French, Abstract in English).
  • Harper PS, Clarke A. (1990) Should we test children for “adult” genetic diseases? Lancet 335:12051206.
  • Henry TR, Leppik IE, Gumnit RJ, Jacobs M. (1988) Progressive myoclonus epilepsy treated with zonisamide. Neurology 38:928931.
  • Iivanainen M, Himberg JJ. (1982) Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 39:236238.
  • Janssen P. (1954) Hereditary Unverricht-Lundborg myoclonus epilepsy in Congolese Negroes. Ann Soc Belg Med Trop 34:113119. (Article in Undetermined Language).
  • Joensuu T, Lehesjoki AE, Kopra O. (2007a) Molecular background of EPM1-Unverricht-Lundborg disease. Epilepsia Nov. 19 [Epub ahead of print].
  • Joensuu T, Kuronen M, Alakurtti K, Tegelberg S, Hakala P, Aalto A, Huopaniemi L, Aula N, Michellucci R, Eriksson K, Lehesjoki AE. (2007b) Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. Eur J Hum Genet 15:185193.
  • Korja M, Kaasinen V, Lamusuo S, Parkkola R, Nygren K, Marttila RJ. (2007) Substantial Thalamostriatal Dopaminergic Defect in Unverricht-Lundborg Disease. Epilepsia 18:17681773.
  • Koskiniemi M, Donner M, Majuri H, Haltia M, Norio R. (1974a) Progressive myoclonus epilepsy. A clinical and histopathological study. Acta Neurol Scand 50:307332.
  • Koskiniemi M, Toivakka E, Donner M. (1974b) Progressive myoclonus epilepsy. Electroencephalographical findings. Acta Neurol Scand 50:333359.
  • Koskiniemi M, Van Vleymen B, Hakamies L, Lamusuo S, Taalas J. (1998) Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 64:344348.
  • Kyllerman M, Sommerfelt K, Hedstrom A, Wennergren G, Holmgren D. (1991) Clinical and neurophysiological development of Unverricht-Lundborg disease in four Swedish siblings. Epilepsia 32:900909.
  • Lafreniere RG, Rochefort DL, Chretien N, Rommens JM, Cochius JI, Kalviainen R, Nousiainen U, Patry G, Farrell K, Soderfeldt B, Federico A, Hale BR, Cossio OH, Sorensen T, Pouliot MA, Kmiec T, Uldall P, Janszky J, Pranzatelli MR, Andermann F, Andermann E, Rouleau GA. (1997) Unstable insertion in the 5′ flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nat Genet 15:298302.
  • Lalioti MD, Scott HS, Buresi C, Rossier C, Bottani A, Morris MA, Malafosse A, Antonarakis SE. (1997) Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 386:847851.
  • Lalioti MD, Scott HS, Genton P, Grid D, Ouazzani R, M'Rabet A, Ibrahim S, Gouider R, Dravet C, Chkili T, Bottani A, Buresi C, Malafosse A, Antonarakis SE. (1998) A PCR amplification method reveals instability of the dodecamer repeat in progressive myoclonus epilepsy (EPM1) and no correlation between the size of the repeat and age at onset. Am J Hum Genet 62:842847.
  • Lehesjoki AE, Eldridge R, Eldridge J, Wilder BJ, De La Chapelle A. (1993) Progressive myoclonus epilepsy of Unverricht-Lundborg type: a clinical and molecular genetic study of a family from the United States with four affected sibs. Neurology 43:23842386.
  • Lehesjoki AE, Koskiniemi M. (1999) Progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia 40(Suppl 3):2328.
  • Lehesjoki AE, Kälviäinen R. (2007) Unverricht-Lundborg disease. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997–2007. Updated 18-Sep-2007. Available at http://www.genetests.org. Accessed [03-Jan-2008].
  • Lundborg H. (1903) Die progressive Myoclonus-Epilepsie (Unverricht's Myoclonie). Almqvist and Wiksell, Uppsala .
  • Magaudda A, Gelisse P, Genton P. (2004) Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 45:678681.
  • Magaudda A, Ferlazzo E, Nguyen VH, Genton P. (2006) Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia 47:860866.
  • Mascalchi M, Michelucci R, Cosottini M, Tessa C, Lolli F, Riguzzi P, Lehesjoki AE, Tosetti M, Villari N, Tassinari CA. (2002) Brainstem involvement in Unverricht-Lundborg disease (EPM1): an MRI and (1)H MRS study. Neurology 58:16861689.
  • Mazarib A, Xiong L, Neufeld MY, Birnbaum M, Korczyn AD, Pandolfo M, Berkovic SF. (2001) Unverricht-Lundborg disease in a five-generation Arab family: instability of dodecamer repeats. Neurology 57:10501054.
  • Medina MT, Martinez-Juarez IE, Duron RM, Genton P, Guerrini R, Dravet C, Bureau M, Perez-Gosiengfiao KT, Amador C, Bailey JN, Chaves-Sell F, Delgado-Escueta AV. (2005) Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood. Adv Neurol 95:307323.
  • Mervaala E, Andermann F, Quesney LF, Krelina M. (1990) Common dopaminergic mechanism for epileptic photosensitivity in progressive myoclonus epilepsies. Neurology 40(1):5356.
  • Moulard B, Genton P, Grid D, Jeanpierre M, Ouazzani R, Mrabet A, Morris M, LeGuern E, Dravet C, Mauguiere F, Utermann B, Baldy-Moulinier M, Belaidi H, Bertran F, Biraben A, Ali Cherif A, Chkili T, Crespel A, Darcel F, Dulac O, Geny C, Humbert-Claude V, Kassiotis P, Buresi C, Malafosse A. (2002) Haplotype study of West European and North African Unverricht-Lundborg chromosomes: evidence for a few founder mutations. Hum Genet 111:255262.
  • Moulard B, Darcel F, Mignard D, Jeanpierre M, Genton P, Cartault F, Yaouanq J, Roubertie A, Biraben A, Buresi C, Malafosse A. (2003) Founder effect in patients with Unverricht-Lundborg disease on reunion island. Epilepsia 44:13571360.
  • Norio R, Koskiniemi M. (1979) Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet 15:382398.
  • Parmeggiani A, Lehesjoki AE, Carelli V, Posar A, Santi A, Santucci M, Gobbi G, Pini A, Rossi PG. (1997) Familial Unverricht-Lundborg disease: a clinical, neurophysiologic, and genetic study. Epilepsia 38:637641.
  • Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J, D'Amato E, Ramirez L, Faham M, Koskiniemi M, Warrington JA, Norio R, Dela Chapelle A, Cox DR, Myers, RM. (1996) Mutations in the gene encoding Sclence 271:17311734.
  • Remy C, Genton P. (1991) Effect of high dose of oral piracetam on myoclonus in progressive myoclonus epilepsy. (Mediteranean myoclonus). Epilepsia 32:6.
  • Shahwan A, Farrell M, Delanty N. (2005) Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 4:239248.
  • Shakir RA, Khan RA, Al-Zuhair AG. (1992) Progressive myoclonic ataxia without ragged red fibres: Unverricht-Lundborg disease vs Ramsay Hunt syndrome. Acta Neurol Scand 86:470473.
  • Shields WD. (2004) Diagnosis of infantile spasms, Lennox-Gastaut syndrome, and progressive myoclonic epilepsy. Epilepsia 45(Suppl 5):24.
  • Smith B, Shatz R, Elisevich K, Bespalova IN, Burmeister M. (2000) Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia 41:10461048.
  • Somerville ER, Olanow CW. (1982) Valproic acid. Treatment of myoclonus in dyssynergia cerebellaris myoclonica. Arch Neurol 39:527528.
  • Tassinari CA, Bureau-Paillas M, Dalla Bernardina B, Grasso E, Roger J. (1974) Electroencephalographic study of myoclonic cerebellar dyssynergia with epilepsy (Ramsay-Hunt syndrome) Rev Electroencephalogr Neurophysiol Clin 44074428. (Article in French).
  • Truong D, Tai KK. (2005) Effect of Brivaracetam (ucb 34714) in a rat model of post-hypoxic myoclonus. UCB code: RRLE05J1201.
  • Unverricht H. (1891) Die Myoclonie. Franz Deuticke, Leipzig .
  • Virtaneva K, D'Amato E, Miao J, Koskiniemi M, Norio R, Avanzini G, Franceschetti S, Michelucci R, Tassinari CA, Omer S, Pennacchio LA, Myers RM, Dieguez-Lucena JL, Krahe R, De La Chapelle A, Lehesjoki AE. (1997) Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet 15:393396.
  • Vistorte A, Sardinas N, Esteban EM, Vargas-Diaz J, Novoa-Lopez L, Rojas-Massippe E, Pestana EM. (1999) Progressive myoclonic epilepsy: clinical characteristics of 18 patients. Rev Neurol 29:102104.
  • Von Rosenstiel P. (2007) Brivaracetam (UCB 34714). Neurotherapeutics 4:8487.